Oral News and Research

RSS

Ponatinib thwarts T315I gene mutation in chronic myeloid leukemia

A previously invincible mutation in chronic myeloid leukemia (CML) has been thwarted by an investigational drug in a phase I clinical trial reported in the current edition of The New England Journal of Medicine.

29 Nov 2012

Regorafenib phase III results strongly support use in GIST

Regorafenib is effective for patients with gastrointestinal stromal tumors who have failed to respond to treatment with imatinib and sunitinib, trial results show.

29 Nov 2012

Nasolabial lip reconstruction provides favorable functional, aesthetic outcomes

Lip reconstruction with the musculocutaneous nasolabial flap following lip resection achieves good functional and aesthetic outcomes, research suggests.

29 Nov 2012

Patient adherence predicts ankle surgery healing

Focusing on postoperative care may be the optimal way of reducing healing complications following ankle fracture surgery, say US researchers.

29 Nov 2012

Periodontal disease identified using salivary biomarkers

Markers of inflammation found in saliva could be used to identify periodontal disease in large epidemiologic surveys, avoiding the need for cumbersome and expensive tests, suggest researchers.

29 Nov 2012

Pfizer completes acquisition of NextWave Pharmaceuticals

Pfizer Inc. today announced that it has completed its acquisition of NextWave Pharmaceuticals, Inc., a privately held, specialty pharmaceutical company focused on the development and commercialization of products for the treatment of attention deficit hyperactivity disorder (ADHD).

29 Nov 2012

Gilead Sciences receives EC approval for Viread to treat HIV-1 infected children

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for two new indications for once-daily Viread (tenofovir disoproxil fumarate).

28 Nov 2012

Children's caries history predicts future tooth decay

Having a history of dental caries significantly increases a child's chances of developing further caries, indicate study results.

27 Nov 2012

Simple measures halve ventilator-associated pneumonia

Adding a bundle of low-cost interventions to surveillance significantly reduces rates of ventilator-associated pneumonia in adult intensive care units in developing countries, shows an international study.

27 Nov 2012

FDA clears Avaxia’s AVX-470 IND for treatment of ulcerative colitis

Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract, announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AVX-470 for the treatment of ulcerative colitis.

27 Nov 2012

With administration's support, Supreme Court orders review of 'Obamacare' challenge

The Supreme Court Monday told a lower court to consider several issues left unresolved by the justices' June ruling upholding the Affordable Care Act, in a move backed by the Obama administration.

27 Nov 2012

Some nicotine-free snus products can increase risk of caries

It is a myth that snus (Swedish snuff) users today have fewer dental caries. On the contrary, some types of nicotine-free snus contain both carbohydrates and starch that increase the risk of cavities. Those are the findings of a thesis from Sahlgrenska Academy, University of Gothenburg, Sweden.

27 Nov 2012

Children with asthma benefit from cognitive behaviour therapy programme

Researchers have found that a programme of cognitive behaviour therapy delivered by nurses to children who had asthma and anxiety improved the children's quality of life scores and reduced the risk of escalation of treatment.

27 Nov 2012

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Seattle Genetics, Inc. announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL).

26 Nov 2012

Interim GALAXY Phase 2b lung cancer study results to be presented at APLCC 2012

Synta Pharmaceuticals Corp. announced today that interim results of the Phase 2b portion of the GALAXY program will be presented on November 28, 2012 at 12:15 p.m. (JST) during the "Highlights of Oral Presentations" session at the Fifth Asia Pacific Lung Cancer Conference (APLCC 2012) in Fukuoka City, Japan.

26 Nov 2012

Smoking-related diabetes a modifiable risk factor

Cigarette smoking is a modifiable risk factor for impaired insulin secretion in Japanese men, show study findings.

23 Nov 2012

Smoking-related diabetes a modifiable risk factor

Cigarette smoking is a modifiable risk factor for impaired insulin secretion in Japanese men, show study findings.

23 Nov 2012

Antibiotic prescribing rates raise concerns over e-visits

E-visits offer a comparable standard of care to traditional physician office visits but antibiotic prescribing rates are higher, particularly for urinary tract infections, say US investigators.

23 Nov 2012

Osteoporosis medication Aclasta now available on Canadian public drug plans

Osteoporosis Canada congratulates the Ontario government, the New Brunswick government, the Saskatchewan government and the British Columbia government for providing access to a new osteoporosis medication. Aclasta (zoledronic acid) is now available on public and private drug plans in Ontario, BC, SK, and NB meaning Canadians at high risk for fractures have access to increased treatment options.

23 Nov 2012

Bowel cancer and GIST patients could benefit from novel oral drug

Two phase 3 trials, published in The Lancet, have shown that a novel oral drug called regorafenib could offer survival benefits to people with bowel (colorectal) cancer or gastrointestinal stromal tumour (GIST) following failure of existing treatments.

22 Nov 2012